First Outbreak of KPC-3-Producing *Klebsiella pneumoniae* (ST258) Clinical Isolates in a Mexican Medical Center


Subdirección Epidemiología Hospitalaria e Infectología y Laboratorio Clínico, Hospital General Manuel Gea González, Ciudad de México, México; Instituto Nacional de Salud Pública (INSP), Centro de Investigaciones Sobre Enfermedades Infecciosas, Departamento de Diagnostico Epidemiológico, Cuernavaca, Morelos, México; Departamento de Ecología de Agentes Patógenos, Hospital General Manuel Gea González, Ciudad de México, México; Departamento de Microbiología y Parasitología Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México

A KPC-producing *Klebsiella pneumoniae* isolate was first described in the United States (1), and strains with the carbapenemase enzyme have more recently been described as having a global spread (2). These KPC-type carbapenemases belong to molecular class A β-lactamases, and they are able to hydrolyze carbapenems and to confer resistance to broad-spectrum antibiotics (3). Risk factors associated with the acquisition of carbapenemase-producing *K. pneumoniae* bacteria include prolonged hospitalization, time in the intensive care unit (ICU), invasive devices, immunosuppression, and the use of multiple antibiotic agents before initial culture (4). In Mexico, no KPC carbapenemase has been described in recent studies of extended spectrum β-lactamase (ESBL)-producing *K. pneumoniae* (5, 6).

We report the first outbreak of KPC-3-producing *K. pneumoniae* isolates of sequence type (ST) 258 in a hospital in Mexico City, along with their epidemiologic and molecular characteristics.

During a 9-month period (January to September 2010), we identified 22 patients (between 21 and 83 years of age) and 2 health workers with an imipenem-resistant *K. pneumoniae* isolate, identified by means of the MicroScan Walkaway 96 automated system (Siemens/Dade-Behring, Sacramento, CA, USA). ESBL production assays were performed using the disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines (1, 7), and 11/24 isolates (45.8%) were ESBL producers. However, all isolates were positive for carbapenemase production by the modified Hodge test (1, 7). Antibiotic susceptibility testing was carried out by the microdilution method, following CLSI recommendations (1, 8). All isolates were resistant to most of the antimicrobials tested (ceftazidime, cefotaxime, piperacillin, ciprofloxacin, imipenem, meropenem, and gentamicin), and they were susceptible to tigecycline and colistin, for which the susceptibility breakpoints proposed by the European Committee on Antimicrobial Susceptibility Testing (www.eucast.org) were used (2 μg/ml for tigecycline and colistin) (Table 1). Typing for *bla*<sub>CTX</sub>-, *bla*<sub>SHV</sub>-, *bla*<sub>TEM</sub>-, and *bla*<sub>KPC</sub>-type genes was carried out by PCR (6, 9) on a PerkinElmer/Applied Biosystems 3730 DNA sequencing system (Applied Biosystems, PerkinElmer, Foster City, CA, USA). For the 11 ESBL-producing *K. pneumoniae* isolates, the ESBL genes were not identified in the PCR screen, and the *K. pneumoniae* chromosomal and plasmidic β-lactamases corresponded to SHV-11 and TEM-1, respectively. Nevertheless, the KPC-3 gene was the carbapenemase enzyme identified in all isolates.

Genomic DNA was analyzed by pulsed-field gel electrophoresis (PFGE) (10, 11); by following the criteria of Tenover et al. (11) and using GelCompar II software (Applied Math, Kortrijk, Belgium), three clonal groups (A, B, and C) and two unrelated isolates were revealed (see Fig. S1 in the supplemental material). Two of the isolates (6420 and 6219) were recovered from the hands of health care personnel and corresponded to isolates from clonal groups B and C (Table 1). Multilocus sequence typing (MLST) was carried out (12), and all KPC-3-producing *K. pneumoniae* isolates belonged to ST258 (Table 1), which has been described as a pandemic clone (13) and is part of clonal complex 292 (14). The identification of isolates with different phylogenetic relationships by PFGE but with the same MLST profile is consistent, according to Vimont et al. (15).

Plasmid analysis was carried out for all isolates (16); one to four high-molecular-weight plasmids were detected in the isolates (Table 1). According to the plasmid profiles, mating experiments were carried out in five isolates (17), and transfer of imipenem resistance was unsuccessful. In order to identify the replicon that contains the KPC-3 gene, a Southern hybridization experiment was carried out using a nonradioactive probe obtained by PCR amplification from the entire KPC-3 gene (ECL direct nucleic acid labeling and detection system; GE Healthcare, Piscataway, NJ, USA) (9). In most isolates, positive signals from the KPC-3 gene were obtained from both a 270-kb and a 70-kb plasmid (data not shown); however, the gene was identified in other plasmids (200, 160, 140, and 120 kb) as well (Table 1). Plasmid preparations obtained by means of ion exchange columns (Qiagen, Valencia, CA, USA) were transformed into *Escherichia coli* TOP10 by electroporation and, once separated in different cells, plasmids were digested with EcoRI enzyme. The restriction pattern revealed two 270- and 70-kb backbone plasmids with imipenem (1 μg/ml), kanamycin (25 μg/ml), gentamicin (16 μg/ml), and ceftazidime (1 μg/ml) resistance and imipenem (1 μg/ml), tetracycline (15 μg/ml), and ceftazidime (1 μg/ml) resistance phenotypes, respectively. All plasmid incompatibility groups were screened using PCR-based replicon typing (18, 19), and the incompatibility...
groups IncF (FIA, FIB, and FIIIs) and repF were identified in both plasmids and confirmed by Southern hybridization (data not shown), using a nonradioactive probe obtained by PCR-based replicon typing.

This is the first report of an outbreak of hospital-acquired KPC-3-producing \textit{K. pneumoniae} isolates in Mexico; in addition, two different plasmids encoding the KPC-3 carbapenemase were identified. At the beginning of the outbreak, a misdiagnosis of KPC-producing \textit{K. pneumoniae} isolates was identified. At the end of the outbreak, a high crude mortality rate (55%) was determined. Moreover, this mortality corresponded to patients with a KPC-producing \textit{K. pneumoniae} isolate culture, a respiratory tract infection, and mechanical ventilation, constituting recognized risk factors (4). Unfortunately, mortality due to this outbreak was higher than the previously reported figures (20). Our considerations on such mortality include the following: before identifying the first isolate of KPC-producing \textit{K. pneumoniae}, we did not use phenotypic methods for carbapenemase screening, which caused a delay in terms of diagnosis and appropriate treatment; also, the use of a tigecycline-colistin combination at the beginning of the outbreak could have been helpful, but colistin was not available in our institution. The spread of \textit{K. pneumoniae} with KPC carbapenemases in Mexican hospitals should be evaluated by multicenter epidemiological studies, since these \textit{K. pneumoniae} isolates belonging to the international epidemic clone ST258 constitute a high-risk factor for nosocomial infections.

### ACKNOWLEDGMENTS

We thank Christine Lascols, COFEPRIS (Mexico), José Luis Méndez-Sánchez, and Fernando Reyna-Flóres for their technical assistance. This work was supported by grants 136339 and 130224 from CONACyT (Mexican Council for Science and Technology). All authors declare no financial or personal relationships with other people or organizations that could have inappropriately influenced their work.

### REFERENCES


### TABLE 1 Characteristics of KPC-3 \textit{K. pneumoniae} ST258 clinical isolates

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Isolation date (day/mo/yr)</th>
<th>Ward</th>
<th>Sample origin</th>
<th>Plasmid pattern (kb)</th>
<th>MIC (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6406</td>
<td>03/08/2010</td>
<td>ICU</td>
<td>Respiratory tract</td>
<td>A 258</td>
<td>120 &gt; 70</td>
</tr>
<tr>
<td>6407</td>
<td>25/08/2010</td>
<td>ICU</td>
<td>Respiratory tract</td>
<td>A 258</td>
<td>270,70</td>
</tr>
<tr>
<td>6408</td>
<td>16/04/2010</td>
<td>GS</td>
<td>Surgical wound</td>
<td>A 258</td>
<td>270</td>
</tr>
<tr>
<td>6411</td>
<td>27/07/2010</td>
<td>ICU</td>
<td>Biological fluids</td>
<td>A 258</td>
<td>270</td>
</tr>
<tr>
<td>6412</td>
<td>20/09/2010</td>
<td>GS</td>
<td>Surgical wound</td>
<td>A 258</td>
<td>270, 200</td>
</tr>
<tr>
<td>6413</td>
<td>16/03/2010</td>
<td>ICU</td>
<td>Biological fluid</td>
<td>A 258</td>
<td>270, 70</td>
</tr>
<tr>
<td>6421</td>
<td>30/01/2010</td>
<td>IM</td>
<td>Urine</td>
<td>A 258</td>
<td>270, 140</td>
</tr>
<tr>
<td>6414</td>
<td>15/06/2010</td>
<td>ICU</td>
<td>Biological fluid</td>
<td>B 258</td>
<td>270, 70</td>
</tr>
<tr>
<td>6415</td>
<td>15/02/2010</td>
<td>ER</td>
<td>Respiratory tract</td>
<td>B 258</td>
<td>70</td>
</tr>
<tr>
<td>6416</td>
<td>20/02/2010</td>
<td>ER</td>
<td>Respiratory tract</td>
<td>B 258</td>
<td>270, 70</td>
</tr>
<tr>
<td>6417</td>
<td>18/02/2010</td>
<td>IM</td>
<td>Respiratory tract</td>
<td>B 258</td>
<td>200, 100, 70</td>
</tr>
<tr>
<td>6418</td>
<td>17/02/2010</td>
<td>ICU</td>
<td>Respiratory tract</td>
<td>B 258</td>
<td>270, 110, 70</td>
</tr>
<tr>
<td>6420</td>
<td>16/02/2010</td>
<td>ICU</td>
<td>Hands of health</td>
<td>B 258</td>
<td>270, 230, 70</td>
</tr>
<tr>
<td>6423</td>
<td>29/01/2010</td>
<td>IM</td>
<td>Urine</td>
<td>B 258</td>
<td>270, 200, 100, 70</td>
</tr>
<tr>
<td>6424</td>
<td>26/04/2010</td>
<td>ICU</td>
<td>Respiratory tract</td>
<td>B 258</td>
<td>270, 160, 70</td>
</tr>
<tr>
<td>6422</td>
<td>31/01/2010</td>
<td>IM</td>
<td>Respiratory tract</td>
<td>B 258</td>
<td>270, 120, 70</td>
</tr>
<tr>
<td>6440</td>
<td>02/04/2010</td>
<td>ICU</td>
<td>Respiratory tract</td>
<td>C 258</td>
<td>270, 160</td>
</tr>
<tr>
<td>6419</td>
<td>16/02/2010</td>
<td>GS</td>
<td>Hands of health</td>
<td>C 258</td>
<td>270, 70</td>
</tr>
<tr>
<td>6439</td>
<td>15/04/2010</td>
<td>ICU</td>
<td>Respiratory tract</td>
<td>C 258</td>
<td>270</td>
</tr>
<tr>
<td>6490</td>
<td>28/06/2010</td>
<td>GS</td>
<td>Biological fluid</td>
<td>C 258</td>
<td>270, 100, 70</td>
</tr>
<tr>
<td>9900</td>
<td>12/02/2010</td>
<td>ICU</td>
<td>Surgical wound</td>
<td>C 258</td>
<td>270, 100, 70</td>
</tr>
<tr>
<td>6410</td>
<td>11/04/2010</td>
<td>IM</td>
<td>Blood</td>
<td>NR 258</td>
<td>270, 70</td>
</tr>
<tr>
<td>9901</td>
<td>12/08/2010</td>
<td>ICU</td>
<td>Biological fluid</td>
<td>NR 258</td>
<td>270, 160, 70</td>
</tr>
</tbody>
</table>

\[ a \text{ ICU, intensive care unit; GS, general surgery; IM, internal medicine; ER, emergency room.} \]
\[ b \text{ NR, not related.} \]
\[ c \text{ The colistin MIC was 0.5 µg/ml for all isolates. CAZ, ceftazidime; CTX, cefotaxime; PIP, piperacillin; CIP, ciprofloxacin; IPM, imipenem; CLA, clavulanic acid; MEM, meropenem; GEN, gentamicin; TGC, tigecycline.} \]


